Literature DB >> 16769130

A comparative indirect ELISA for the detection of henipavirus antibodies based on a recombinant nucleocapsid protein expressed in Escherichia coli.

Ji-Ming Chen1, Meng Yu, Chris Morrissy, Yong-Gang Zhao, Greer Meehan, Ying-Xue Sun, Qing-Hua Wang, Wei Zhang, Lin-Fa Wang, Zhi-Liang Wang.   

Abstract

The indirect ELISA is a simple and useful method for detection of pathogen-specific antibodies in animal sera. However, non-specific or background binding is often a problem, especially when recombinant proteins from Escherichia coli are used. In this study, a comparative indirect ELISA in which the total reactivity and the background binding were determined simultaneously on the same ELISA plate was reported. The background was determined by incubation of the test sera with excess free antigen to block specific binding. The sample was considered positive only when its total reactivity reading was higher than a pre-determined cut-off value and the ratio of the total reactivity to the background reading was more than 2.0. Using this approach, an antibody assay for henipaviruses using a recombinant Nipah virus nucleocapsid protein expressed in E. coli was developed. A total of 919 negative serum samples were tested in this assay and the specificity was 95.8%. In addition, eight positive experimental serum samples all tested positive. The use of recombinant protein as the ELISA antigen, instead of inactivated virus antigens, will be of significant advantage for countries where there is no facility of Biosafety level 4 to handle this group of zoonotic viruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769130     DOI: 10.1016/j.jviromet.2006.05.003

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA.

Authors:  Cheng-Feng Chiang; Michael K Lo; Paul A Rota; Christina F Spiropoulou; Pierre E Rollin
Journal:  Virol J       Date:  2010-06-03       Impact factor: 4.099

2.  Nipah virus infection: current scenario.

Authors:  D D Kulkarni; C Tosh; G Venkatesh; D Senthil Kumar
Journal:  Indian J Virol       Date:  2013-11-07

3.  Development of a neutralization assay for Nipah virus using pseudotype particles.

Authors:  Azaibi Tamin; Brian H Harcourt; Michael K Lo; James A Roth; Mike C Wolf; Benhur Lee; Hana Weingartl; Jean-Christophe Audonnet; William J Bellini; Paul A Rota
Journal:  J Virol Methods       Date:  2009-03-09       Impact factor: 2.014

4.  Antibodies to henipavirus or henipa-like viruses in domestic pigs in Ghana, West Africa.

Authors:  David T S Hayman; Lin-Fa Wang; Jennifer Barr; Kate S Baker; Richard Suu-Ire; Christopher C Broder; Andrew A Cunningham; James L N Wood
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

5.  Henipavirus neutralising antibodies in an isolated island population of African fruit bats.

Authors:  Alison J Peel; Kate S Baker; Gary Crameri; Jennifer A Barr; David T S Hayman; Edward Wright; Christopher C Broder; Andrés Fernández-Loras; Anthony R Fooks; Lin-Fa Wang; Andrew A Cunningham; James L N Wood
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

6.  Indirect ELISA based on Hendra and Nipah virus proteins for the detection of henipavirus specific antibodies in pigs.

Authors:  Kerstin Fischer; Sandra Diederich; Greg Smith; Sven Reiche; Vinicius Pinho Dos Reis; Eileen Stroh; Martin H Groschup; Hana M Weingartl; Anne Balkema-Buschmann
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

Review 7.  Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review.

Authors:  Raj Kumar Singh; Kuldeep Dhama; Sandip Chakraborty; Ruchi Tiwari; Senthilkumar Natesan; Rekha Khandia; Ashok Munjal; Kranti Suresh Vora; Shyma K Latheef; Kumaragurubaran Karthik; Yashpal Singh Malik; Rajendra Singh; Wanpen Chaicumpa; Devendra T Mourya
Journal:  Vet Q       Date:  2019-12       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.